Advanced non-small-cell lung cancer in the elderly

Clinical Lung Cancer

Volumn 10, Issue 3, 2009, Pages 158-167

  Vamvakas, Lambros ^a   Saloustros, Emmanouel ^a   Karampeazis, Athanasios ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Chemotherapy; Comprehensive geriatric assessment; Elderly patients; Platinum based combinations; Quality of life; Survival; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; JCOG 9812; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ACNE; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAVASATION; FATIGUE; FEBRILE NEUTROPENIA; GERIATRIC ASSESSMENT; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PROTEINURIA; RASH; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; AGED; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; REVIEW;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GERIATRIC ASSESSMENT; HUMANS; LUNG NEOPLASMS;

EID: 67649411994     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.022     Document Type: Review

References (92)

1. Ahmedin J, Siegel R, Ward E. Cancer statistics 2007. CA Cancer J Clin 2007; 57:43-66.
2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-6. (Pubitemid 32911406)
3. Ettinger DS, Cox JD, Ginsberg RJ, et al. NCCN Non-small cell Lung Cancer Practice Quidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996; 10(suppl 11):81-111.
4. American Society of Clinical Oncology. Outcome of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1994; 14:671-9.
5. Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review 1975-2000. Available at: http://seer.cancer.gov/csr/1975-2000. Accessed: April 15, 2009.
6. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997; 33:2313-4.
7. Havlik RJ, Yancik R, Long S, et al. The National Cancer Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994; 74(suppl 7):2101-6.
8. Wingo PA, Cardinez CJ, Landis SH, et al. Long term trends in cancer mortality in the United States. Cancer 2003; 97(suppl 12):3133-275.
9. Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol 2002; 3:289-97.
10. Repetto L, Venturino A, Fratino L, et al. Geriatric oncology: A clinical approach to the older patient with cancer. Eur J Cancer 2003; 39:870-80.
11. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-72.
12. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: Why so badly treated? Lancet 1990; 335:1020-2.
13. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-7.
14. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21:1383-9.
15. Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? J Clin Oncol 2003; 21:1618-23.
16. Perrone F, Gallo C, Gridelli C. Re: Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94:1029-31.
17. Jatoi A, Hillman S, Stella P, et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005; 23:9113-9.
18. Unger J, Coltman C, Crowley J, et al. Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials. J Clin Oncol 2006; 24:141-4.
19. Balducci L. Geriatric Oncology. Crit Rev Oncol Hematol 2003; 46:211-20.
20. de Groot V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003; 56:221-9.
21. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
22. Parmelee PA, Thuras PD, Katz IR, et al. Validation of the cumulative illness rating scale in a geriatric residential population [see comments]. J Am Geriatr Soc 1995; 43:130-7.
23. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16:622-6.
24. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus. J Chronic Dis 1974; 27:387-404.
25. Basso U, Monfardini S. Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care (Engl) 2004; 13:424-33.
26. Balducci L, Stanta G. Cancer in the frail patient: a coming epidemic. Hematol Oncol Clin North Am 2000; 14:235-50.
27. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults. Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-56.
28. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003; 114:180-7.
29. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-smallcell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005; 23:6865-72.
30. Firat S, Bousamra M, Gore E, et al. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52:1047-57.
31. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291:2441-7.
32. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120:104-10.
33. Asmis T, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008; 26:54-9.
34. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
35. Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only: a multicentre randomised phase III trial. Eur J Cancer 1998; 34:1036-44.
36. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995; 71:366-70.
37. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188-94.
38. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4:14-22.
39. Ruckdeschel JC, Finkelstein DM, Mason BA, et al. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V - a randomized comparison of four cisplatin-containing regimens. J Clin Oncol 1985; 3:72-9.
40. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18:122-30.
41. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of highdose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:3390-9. (Pubitemid 30821916)
42. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16:2459-65.
43. Georgoulias V, Ardavanis A, Agelidou M, et al. Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22:2602-9.
44. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:66-72.
45. Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicentre phase II study. Lung Cancer 2000; 27:75-80.
46. Martoni A, Di Fabio F, Guaraldi M, et al. Prospective phase II study of singleagent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer. Am J Clin Oncol 2001; 24:614-7.
47. Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001; 31:277-84.
48. Nakamura Y, Sekine I, Furuse K, et al. Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients aged 70 years of age or older and patients under 70 years of age. Cancer Chemother Pharmacol 2000; 46:114-8.
49. Fidias P, Supko JG, Martins R, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001; 7:3942-9.
50. Garbo L, Marsland T, Garfield D, et al. A phase II study of weekly paclitaxel (Taxol) in stage IIIB, IV, or relapsed after local therapy, non-small cell lung cancer (NSCLC) patients with a performance status of 2 and/or 70 years (yrs) of age, with (Paraplatin) administered at disease progression. Proc Am Soc Clin Oncol 2001; 20:267b (Abstract 2821).
51. West W, Birch R, Sysel I, et al. A phase II trial of weekly paclitaxel in elderly patients or those with decreased performance status with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20:258b (Abstract 2782).
52. Rossi D, Dennetta D, Ugolini M, et al. Weekly paclitaxel in elderly patients (aged ≥ 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer 2008; 9:280-4.
53. Lilenbaum R, Rubin M, Samuel J, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2007; 4:306-11.
54. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24:3657-63. (Pubitemid 46630541)
55. Karampeazis L, Vamvakas A, Agelidou, et al. Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): A randomized phase II Hellenic Oncology Research Group trial. J Clin Oncol 2007; 25(18 suppl):412s (Abstract 7615).
56. Leong SS, Toh CK, Lim WT, et al. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2007; 3:230-6.
57. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22:330-53.
58. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: Results of an international expert panel. J Clin Oncol 2005; 23:3125-37.
59. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15:2996-3018.
60. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow- up of non-small-cell lung cancer (NSCLC). Ann Oncol 2001; 12:1049-50.
61. Tang M, Davidoff AJ, Mullins CD, et al. Chemotherapy (C) and survival among 21, 441 elderly (E) patients (pts) with advanced (adv) NSCLC: Analysis of SEER-Medicare claim data 1997-2002. J Clin Oncol 2008; 26(15 suppl):446s (Abstract 8090).
62. Minami H, Ohe Y, Niho S, et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: Why is toxicity increased in elderly patients? J Clin Oncol 2004; 22:2901-8.
63. Kubota K, Furuse K, Kawahara M, et al. Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40:469-74.
64. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94:173-81.
65. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
66. Fossella F, Pereira JR, von Pawel et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2005; 23:8389-95.
67. Fossella F, Belani CP. Phase III study (TAX 326) of docetaxel - cisplatin and docetaxel - carboplatin versus vinorelbine - cisplatin for the first-line treatment of advanced/metastaticnon-small cell lung cancer: Analyses in elderly patients. Cancer 2005; 104:2766-6.
68. Gridelli C, Maione P, Illiano A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol 2007; 25:4663-9.
69. Ohe Y, Niho S, Kakinuma R, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004; 15:45-50.
70. Maestu IC, Gomez-Aldaravi L, Torregrossa MD, et al. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 2003; 42:345-54.
71. Okamoto I, Moriyama E, Kishi H, et al. Multicenter phase II study of the combination of carboplatin and paclitaxel as first line treatment in elderly patients with advanced non small cell lung cancer. J Clin Oncol 2004; 23(suppl):672 (Abstract 7239).
72. Choi IS, Kim BS, Park SR, et al. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non small cell lung cancer. Lung Cancer 2003; 39:99-101.
73. Molinier O, Milleron B, Breton JL, et al. Multicenter phase II trial of carboplatin and weekly paclitaxel as first-line treatment in elderly patients with non small cell lung cancer: Preliminary results. Proc Am Soc Clin Oncol 2003; 22(suppl):693 (Abstract 2786).
74. Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007; 110:2027-34.
75. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:4405-11.
76. Tibaldi C, Bernardini I, Chella A, et al. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006; 6:401-5.
77. Scagliotti G, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51.
78. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (< 70). Proc Am Soc Clin Oncol 2003; 22(suppl):639 (Abstract 2569).
79. Owonikoko T, Ragin C, Belani C, et al. Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database. J Clin Oncol 2007; 25:5570-7.
80. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. (Pubitemid 44917502)
81. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advancedstage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26:60-5.
82. Sanjay Goel. Reporting of subset analysis: where do we draw the line? J Clin Oncol 2008; 26:2062-3.
83. Merza T, Howard LM, Junagadhwalla M. Exclusions to use of bevacizumab in elderly veterans with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):687s (Abstract 18046).
84. Gridelli C. Treatment of advanced non-small-cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. J Clin Oncol 2008; 26:13-5.
85. Shepherd FA, Rodrigues Pereira J, Tan EH, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
86. Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26:2350-7.
87. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy- naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-6.
88. Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study. J Clin Oncol 2008; 26:4253-60.
89. Ebi N, Semba H, Tokunaga SJ, et al. A phase II trial of gefitinib Monotherapy in chemotherapy-naive patients of 75 years or older with advanced nonsmall cell lung cancer. J Thorac Oncol 2008; 3:1166-71.
90. Atagi S, Kawahara M, Tamura T, et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced nonsmall cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 2005; 35:195-201.
91. Schild SE, Stella PJ, Geyer SM, et al. North Central Cancer Treatment Group The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003; 21:3201-6.
92. Guida C, Maione P, Rossi A, et al. Combined chemo-radiotherapy for locally advanced nonsmall cell lung cancer: Current status and future development. Crit Rev Oncol Hematol 2008; 68:222-32.